🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment.

    Bayer AG

    Prostate cancer

    phase 1 other active

    1 trial

  2. A study to assess safety and efficacy of SOT201 in patients with advance/metastatic cancer

    IO Biotech

    advanced/metastatic solid tumors

    phase 1 other active

    1 trial

  3. A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelodysplastic Syndromes

    Celgene Europe Limited

    Acute Myeloid Leukemia and Myelodysplastic Syndromes

    phase 1 other active

    1 trial

  4. A study to characterise the safety, tolerability and efficacy of LY4170156 in subjects with advanced solid tumors

    Eli Lilly Co.

    Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.

    phase 1 other active

    1 trial

  5. A study to compare Onivyde manufactured at two different production sites in adult participants with advanced cancer in the pancreas

    Ipsen

    Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  6. A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789 in participants with Advanced Small Cell Lung Cancer and other Neuroendocrine Carcinomas

    Hoffmann-La Roche

    Small Cell Lung Cancer and Neuroendocrine Carcinoma

    phase 1 other active

    1 trial

  7. A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy

    Boehringer Ingelheim

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 1 other active

    1 trial

  8. A study to investigate the safety and tolerability of Trastuzumab Deruxtecan in combination with Immunotherapy Agents with and without chemotherapy, as the first treatment option for patients with advanced HER2 over-expressing Non-Small Cell Lung Cancer.

    AstraZeneca AB

    Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (OE)

    phase 1 other active

    1 trial

  9. A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanced cancers

    Janssen-Cilag International N.V.

    Previously treated lymphoma (blood cancer) or solid tumors and NHL

    phase 1 other active

    1 trial

  10. A study to learn BAY 3498264 when given alone or together with sotorasib in participants who have advanced solid cancers with specific genetic changes called KRASG12C mutation

    Bayer AG

    Advanced solid tumors harboring KRAS G12C mutation

    phase 1 other active

    1 trial

  11. A study to learn about the study medicine called PF-08046032 in people with advanced cancers.

    Pfizer Australia Pty Ltd

    Advanced lymphomas (classic Hodgkin lymphoma [cHL], peripheral T cell lymphoma [PTCL], and diffuse large B cell lymphoma [DLBCL]), Solid tumors (eg, NSCLC, HNSCC, and melanoma)

    phase 1 other active

    1 trial

  12. A study to learn how safe the study drug BAY 2416964 (AhR inhibitor) in combination with the treatment pembrolizumab is, how this combination affects the body, the maximum amount that can be given, how it moves into, through and out of the body and its action against advanced solid cancers in adults

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  13. A study to test Aumolertinib in European participants with genetically linked advanced Lung Cancer

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations, Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations

    phase 1 other active

    1 trial

  14. A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in patients with advanced head and neck cancer

    Boehringer Ingelheim

    Advanced head and neck cancer

    phase 1 other active

    1 trial

  15. A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with KRAS mutation.

    Boehringer Ingelheim

    solid tumour harbouring G12C mutation

    phase 1 other active

    1 trial

  16. A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors).

    Boehringer Ingelheim

    solid tumors

    phase 1 other active

    1 trial

  17. A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim

    advanced, unresectable and/or metastatic solid tumors

    phase 1 other active

    1 trial

  18. A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas

    Boehringer Ingelheim

    colorectal carcinoma (CRC)

    phase 1 other active

    1 trial

  19. A study to test different doses of obrixtamig (BI 764532) in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3.

    Boehringer Ingelheim

    Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

    phase 1 other active

    1 trial

  20. A study to test how different doses of BI 1703880 in combination with ezabenlimab are tolerated in people with different types of advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced solid tumours

    phase 1 other active

    1 trial

  21. A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours

    phase 1 other active

    1 trial

  22. A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and neck cancer or liver cancer

    Boehringer Ingelheim

    head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma

    phase 1 other active

    1 trial

  23. A study to test whether treatment with BI 770371 in combination with pembrolizumab with or without cetuximab helps people with head and neck cancer compared with pembrolizumab alone

    Boehringer Ingelheim

    Head and neck squamous cell carcinoma

    phase 1 other active

    1 trial

  24. A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lung cancer that cannot be completely cured.

    CureVac AG

    metastatic squamous non-small cell lung cancer

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources